Boehringer Ingelheim Vetmedica, Inc.
3902 Gene Field Road
St. Joseph, Missouri 64506
Value Through Innovation24 May 2013
December 21, 2010
Pyramid® 5 Changes Its Look
Pyramid® 5 Changes Its Look
Pyramid® 5 Changes Its Look
Boehringer Ingelheim Vetmedica, Inc. has unveiled a new packaging design for Pyramid® 5. The Pyramid brand of vaccines was acquired by Boehringer Ingelheim Vetmedica, Inc. in late 2009 and the product has been sold in the Fort Dodge packaging until now. Pyramid 5 is the first product from the Pyramid family to be presented in the new package.
The new box is still the familiar yellow, but the design now aligns Pyramid 5 more closely with the rest of the Boehringer Ingelheim Vetmedica family of products.
Although the packaging for Pyramid 5 has changed, you’ll still find the same powerful protection to aid in the prevention of disease caused by BRSV, BVD Types 1 and 2, PI3 and IBR. In addition, this product aids in the prevention of persistent BVD Types 1 and 2 infections of fetal calves.
For more information on Pyramid 5, contact your veterinarian or Boehringer Ingelheim Vetmedica, Inc. representative.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
